Fredag 28 November | 09:35:31 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-02-27 08:30 Bokslutskommuniké 2025
2025-11-14 - Kvartalsrapport 2025-Q3
2025-08-01 - Kvartalsrapport 2025-Q2
2025-05-27 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2025-05-26 - Årsstämma
2025-05-22 - Kvartalsrapport 2025-Q1
2025-03-27 - Bokslutskommuniké 2024
2024-12-30 - Extra Bolagsstämma 2025
2024-10-24 - Kvartalsrapport 2024-Q3
2024-10-04 - Extra Bolagsstämma 2024
2024-07-18 - Kvartalsrapport 2024-Q2
2024-04-26 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2024-04-25 - Årsstämma
2024-04-18 - Kvartalsrapport 2024-Q1
2024-02-16 - Bokslutskommuniké 2023
2023-10-25 - Kvartalsrapport 2023-Q3
2023-07-18 - Kvartalsrapport 2023-Q2
2023-04-27 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2023-04-26 - Årsstämma
2023-02-16 - Bokslutskommuniké 2022
2022-11-09 - Kvartalsrapport 2022-Q3
2022-08-17 - Kvartalsrapport 2022-Q2
2022-05-19 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2022-05-17 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-25 - Bokslutskommuniké 2021
2021-12-14 - Extra Bolagsstämma 2021
2021-11-16 - Kvartalsrapport 2021-Q3
2021-08-17 - Kvartalsrapport 2021-Q2
2021-05-14 - Kvartalsrapport 2021-Q1
2021-05-03 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2021-04-18 - Årsstämma
2021-02-25 - Bokslutskommuniké 2020
2020-11-27 - Extra Bolagsstämma 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-07-14 - Kvartalsrapport 2020-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Magle Group bygger på strategiska förvärv som syftar till att driva tillväxt och diversifiera risker. Idag omfattar koncernen tre verksamhetsområden. Magle Chemoswed, en kontraktsutvecklings- och tillverkningsorganisation (CDMO). Magle PharmaCept, ett försäljnings- och marknadsföringsföretag för utveckling och direktförsäljning av koncernens medicintekniska produkter, och Magle Biopolymers A/S, en specialiserad tillverkningsorganisation för Dextran-teknologi.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2025-11-27 08:30:00

As of today, Hans Henrik Lidgard steps down as Chairman of the Board for health reasons and will remain on the Board. In accordance with the procedural rules of the Board of the Company, Vice-Chairman Stig Løkke Pedersen automatically assumes the role of Chairman, effective immediately.

Mr. Pedersen brings nearly 40 years of experience in the pharmaceutical industry, with a proven track record of leadership and strategic development in both international and Nordic markets, having held senior leadership positions at Lundbeck and other global companies.

Under Hans Henrik’s leadership, Magle has transformed from a single-technology venture into a diversified life-science group with operations spanning pharmaceuticals, biomaterials, and medical devices. His vision, entrepreneurial spirit, and commitment to innovation have been instrumental in building the company’s strong foundation and positioning Magle Group as a recognised player within the global life-sciences sector.

In honour of Hans Henrik’s longstanding contribution to Magle and to the broader life-science community, Magle Chemoswed Holding is proud to introduce the Hans Henrik Lidgard Annual Stipend. Awarded each year, the stipend will support master’s thesis work in the field of life sciences, helping to foster the next generation of scientific talent and innovation.

In a statement, Hans Henrik Lidgard said: “It has been an extraordinary journey to see Magle grow from its early vision into the dynamic life-science group it is today. I am immensely proud of what we have achieved together, a company that combines innovation, science, and purpose to improve patient outcomes. I am deeply honoured by the establishment of this annual stipend and confident that, under Stig’s leadership, Magle will continue to build on its legacy and reach even greater heights.”

Mats Pettersson, long-serving member of the Board, added: “We are deeply grateful for Hans Henrik’s remarkable service and commitment over nearly three decades. We warmly welcome Stig to his new role as Chairman and look forward to continuing Magle Group’s growth and innovation under his guidance.”

The Board and management extend their sincere appreciation to Hans Henrik for his exceptional leadership and for remaining actively engaged as a member of the Board. They also welcome Stig Løkke Pedersen as Chairman, confident in his ability to help steer Magle Group towards continued success.